Escala Medical

Industry
Medical Technology
Founded Year
2014
Headquarters
Misgav, Israel
Employee Count
10

Key People

  • Dr. Edit Goldberg - CEO
  • Chen Barak - Founder
  • Ravit Horner - Head of Research and Development
  • Charlie Bradley - U.S. Director of Sales
  • Robert Auerbach - Chairman of the Board

Assessment

Team
Aspect: First-time 10+ yrs
Summary: The leadership team comprises individuals with over a decade of experience in the medical device industry.

Dr. Edit Goldberg, the CEO, and other key members have significant backgrounds in medical devices, particularly in women's health, which is crucial for the company's focus on pelvic organ prolapse solutions.

Clinical Need
Aspect: Very Strong
Summary: Pelvic Organ Prolapse (POP) affects approximately 50% of women worldwide, indicating a substantial unmet clinical need.

Current surgical options for POP are invasive and primarily suitable for advanced stages. Escala's minimally invasive, incision-free device offers a much-needed alternative for early-stage treatment, potentially improving quality of life for millions of women.

Competition
Aspect: First mover
Summary: Escala appears to be among the first to offer a non-surgical, incision-free solution for POP.

While other treatments exist, Escala's approach is unique in its minimally invasive nature, potentially setting the company apart in the market.

Technical Challenge
Aspect: Moderate
Summary: Developing a minimally invasive device for POP presents moderate technical challenges.

The device's development requires careful design to ensure efficacy and safety, but the company's experienced team is well-equipped to address these challenges.

Patent
Aspect: Strong
Summary: Escala holds multiple patents in the 'Medical Or Veterinary Science; Hygiene' category.

The patents protect the unique aspects of Escala's device, potentially preventing competitors from developing similar solutions and securing the company's market position.

Financing
Aspect: Medium
Summary: The company has secured significant funding, including a $4.5 million round in June 2025.

The recent funding round, including investment from the EIC Fund and private investors, provides resources for expansion. However, continued investment will be necessary to support commercialization and market penetration efforts.

Regulatory
Aspect: 510k/PMA
Summary: The device received FDA clearance in 2022 and has been commercially available in the U.S. since 2023.

The FDA clearance validates the device's safety and efficacy, allowing Escala to market and sell the product in the U.S., a key market for medical devices.

Opportunity Rollup

Odds of Success
3.95
Peak Market Share
5.45
Segment CAGR
5.9%
Market Segment
Nephrology and Urology Devices
Market Sub Segment
Pelvic Organ Prolapse Treatment Devices
Year Post Launch Market Penetration (%)
1 0.27
2 0.82
3 1.91
4 3.82
5 5.45

Key Takeaway

Escala Medical's innovative, minimally invasive device addresses a significant unmet need in pelvic organ prolapse treatment, positioning the company for substantial growth in the women's health market.